Navigation Links
Transgenomic, Inc. Reports Second Quarter 2007 Results
Date:8/19/2007

end of the fiscal year."

Mr. Tuttle continued, "Our Pharmaceutical Research Services group performed work for six pharmaceutical companies so far this year, and we signed several new contracts with these and other new partners which will result in continued growth for this division. We are also in the process of increasing resources in our clinical molecular diagnostics lab to further drive growth similar to what we have been experiencing for this business over the last few quarters. Finally, we expect to realize the full impact of the ongoing consolidations and other cost reduction by the fourth quarter of the year. This is a very exciting time for the company as we enjoy the results of our refocusing on strong financial performance in our traditional mutation discovery tools business and substantial growth in our diagnostics laboratory business and Pharmaceutical Research Services business."

Earnings Call

Company management will discuss second quarter 2007 financial results via teleconference on Tuesday, August 14, 2007 at 5:00 p.m. Eastern Time. To access the call via telephone, dial 800-896-8445 or 785-830-1916. The company will also host a live broadcast of the call over the Internet. To listen to the webcast, investors should log on to the company's Investor Relations web page at http://www.transgenomic.com/events.asp?id=6 and follow the instructions provided. An archived recording of the conference call will be available and can be accessed via the web using the same link listed above for 14 days after the call. Investors can also listen to a replay via telephone until 11:59 p.m. Eastern Time on Tuesday, August 28, 2007. Simply dial 800-839-9881 or 402-220-3100 from any telephone.

About Transgenomic: A decade of discovery 1997 - 2007

Transgenomic is a global biotechnology company that provides unique products and services for automated high sensitivity genet
'/>"/>

SOURCE Transgenomic, Inc.

Copyright©2007 PR Newswire.

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. TomoTherapy reports 86% revenue jump, $131M net loss in Q1
2. Sonic Foundry reports GAAP loss as Q2 revenues rise
3. Fiserv reports $113.5 million in Q1 profit
4. Third Wave reports net loss of $18.9M for 2006
5. Musicnotes reports 45 percent growth in 2006
6. Sonic Foundry reports net loss, higher revenue
7. Sonic Foundry reports first cash-positive quarter
8. Merge Healthcare reports $10.8M net loss in Q3
9. Third Wave reports $5.2M third quarter loss
10. Merge Healthcare appoints new CEO, reports $215 million Q2 loss
11. Merge files financial reports by market opening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... Dec. 15 Aethlon Medical, Inc. (OTC ... Jeff Schorey and Dr. Wayne Comper ... Sciences, Inc. (ESI). Both Dr. Schorey and Dr. ... ESI, a wholly owned subsidiary of Aethlon Medical, ... the Hemopurifier®, a medical device being advanced as ...
(Date:12/15/2009)... (NYSE: MOS ) plans to issue its ... tables on Tuesday, January 5, 2010, after the close ... Results will be available on Mosaic,s website at mosaicco.com/investors. ... call with presentation slides on Wednesday, January 6, 2010, ... at 11:00 a.m. Eastern Standard Time (10:00 a.m. Central ...
(Date:12/15/2009)... Dec. 15 On January 20th, 2010, ... for Medical Publication Professionals (ISMPP) will be held ... UK. More than 100 attendees are expected at ... publication professionals, editors, publishers, medical writers and medical ... publications and the impact of guidelines and regulations ...
(Date:12/15/2009)... has announced the launch of several innovative new programs ... in the current economic climate. The first is ... finance legal services over a period of 6, 12, ... their start-up companies. The second is aimed at ... arrangements over 6 to 12 month period at discounted ...
Breaking Biology Technology:Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 2Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 3Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 4Aethlon Medical Appoints Jeff Schorey and Wayne Comper to Exosome Sciences Advisory Board 5Mosaic Announces Second Quarter Fiscal Year 2010 Earnings Release and Conference Call 2Announcing ISMPP EU 2010 - the First European Meeting of the International Society for Medical Publication Professionals, Royal College of Physicians, London, UK, January 20, 2010 2The Prinz Law Office Launches Innovative New Programs to Aid Cash-Strapped Entrepreneurs and Businesses 2
... Graduate Institute,(KGI) today announced that James Greenwood, president ... discuss "The American,Health Care System & the Presidential ... 7th Annual Simon Ramo Distinguished Lecture Series on,Wednesday, ... are thoroughly delighted that Jim Greenwood will serve ...
... Feb. 12 /PRNewswire-FirstCall/ - AEterna Zentaris Inc.,(NASDAQ: ... focused on,endocrine therapy and oncology, today reported that ... linked to doxorubicin,has commenced in its Phase 2 ... begun in December 2007. This open-label,non-comparative multi-center Phase ...
... Nektar,Therapeutics (Nasdaq: NKTR ) announced a ... drug delivery service provider to a,therapeutics drug development ... functions, and strengthen,decision-making and execution within the business ... world-class drug development company,and these changes are a ...
Other Biology Technology:KGI Announces BIO President Greenwood to Address Health Care Reform and the Presidential Race at Simon Ramo Lecture 2KGI Announces BIO President Greenwood to Address Health Care Reform and the Presidential Race at Simon Ramo Lecture 3AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers 2AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers 3AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers 4Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization 2Nektar Announces Restructuring to Complete Its Transition to a Therapeutics Drug Development Organization 3
(Date:12/15/2009)... The mouse is a standard laboratory model organism, ... conventional techniques to analyze blood and blood-forming tissues ... of compact and easy-to-use laboratory resources from Cold ... Mouse Hematology features step-by-step protocols for ... blood, bone marrow, and other hematopoietic tissues in ...
(Date:12/14/2009)... 2009) -- Researchers at Rice University and Baylor College ... can be tracked in real time with MRI as ... a fluorescent dye and kills them with heat. The ... a growing field called "theranostics" that develops technologies physicians ... single procedure. , The research is available online in ...
(Date:12/14/2009)... or for Tasmanian devils biting each other ... the dinosaurs to extinction through the transmission of a ... Biology, highlights the ,paleobiological detective work, of David Varricchio ... to deduce that a protozoan parasite was to blame ... fossils. , The parasite,s modern-day equivalent, which infects birds, ...
Breaking Biology News(10 mins):New source of classical techniques for blood-based studies in the laboratory mouse 2Tracking new cancer-killing particles with MRI 2The Worlds Only Online Marketplace Dedicated to Buying and Selling Gently Used and New Special Needs Equipment 3A DifferentNeedz com 5284 1The Worlds Only Online Marketplace Dedicated to Buying and Selling Gently Used and New Special Needs Equipment 3A DifferentNeedz com 5284 2Parallels Server Bare Metal Launches Building on Parallels 26apos 3B Containers Leadership to Enable Cloud Services Providers to Extend Virtualized S 59039 1Parallels Server Bare Metal Launches Building on Parallels 26apos 3B Containers Leadership to Enable Cloud Services Providers to Extend Virtualized S 59039 2Parallels Server Bare Metal Launches Building on Parallels 26apos 3B Containers Leadership to Enable Cloud Services Providers to Extend Virtualized S 59039 3Parallels Server Bare Metal Launches Building on Parallels 26apos 3B Containers Leadership to Enable Cloud Services Providers to Extend Virtualized S 59039 4Parallels Server Bare Metal Launches Building on Parallels 26apos 3B Containers Leadership to Enable Cloud Services Providers to Extend Virtualized S 59039 5MDLiveCare First TeleHealth Provider to Launch on the Google Health Platform 59034 1MDLiveCare First TeleHealth Provider to Launch on the Google Health Platform 59034 2MDLiveCare First TeleHealth Provider to Launch on the Google Health Platform 59034 3
... with asbestos exposure ?have a higher survival rate when treated ... study finds. , Mesothelioma, a rare but aggressive form of ... and abdomen, is associated with exposure to asbestos. There is ... pemetrexed and cisplatin ?along with the vitamin supplements folic acid ...
... (IBV) causes losses of £23.6M a year to the UK ... to vaccinate chicks against the disease ?one that can be ... A pre-hatching prototype vaccine virus which provides immunity to IBV ... Health (IAH) and vaccine company Intervet UK. It can be ...
... simpler than what scientists had been assuming. A new study, ... Biological Chemistry, provides new information on the inner workings of ... physicians make livers regrow in patients with liver diseases such ... is one of the few organs in the body that ...
Other Biology News:Chemo combination improves survival in asbestos-related cancer 2Chemo combination improves survival in asbestos-related cancer 3In-shell vaccine for chick disease 2Liver regeneration may be simpler than previously thought 2Liver regeneration may be simpler than previously thought 3
... Freedom EVOlyzer is Tecans new Enzyme-Linked Immunosorbent ... processing. Freedom EVOlyzer is a dedicated EVO ... art reader, washer and incubation units operated ... Freedom EVOlyzer is available in three sizes ...
... hormones which belong to the transforming ... superfamily is a large group of ... aspects of development, reproductive function and ... TGF-s, bone morphogenetic proteins, growth differentiation ...
... polypeptide hormones which belong to the ... TGF- superfamily is a large group ... many aspects of development, reproductive function ... incude TGF-s, bone morphogenetic proteins, growth ...
... Activins are polypeptide hormones which belong ... superfamily. The TGF- superfamily is a ... which control many aspects of development, ... Other members incude TGF-s, bone morphogenetic ...
Biology Products: